DNA testing company 23andMe has sold the rights to a new drug that it has developed using its customers’ data. It is the first time the company has signed a deal to license a drug it developed.
The deal for the drug, which is being investigated as a potential treatment for inflammatory diseases, is with
Spanish pharmaceutical company Almirall.
“This is a seminal moment for 23andMe,” Emily Drabant Conley, 23AndMe’s vice-president of business development
told Bloomberg. “We’ve now gone from database to discovery to developing a drug.”
